A detailed history of Northern Trust Corp transactions in Replimune Group, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 549,501 shares of REPL stock, worth $6.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
549,501
Previous 463,259 18.62%
Holding current value
$6.87 Million
Previous $4.17 Million 44.45%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.09 - $11.23 $697,697 - $968,497
86,242 Added 18.62%
549,501 $6.02 Million
Q2 2024

Aug 14, 2024

SELL
$5.01 - $9.46 $102,128 - $192,842
-20,385 Reduced 4.21%
463,259 $4.17 Million
Q1 2024

May 14, 2024

BUY
$6.87 - $9.31 $12,434 - $16,851
1,810 Added 0.38%
483,644 $3.95 Million
Q4 2023

Feb 13, 2024

BUY
$6.75 - $16.18 $196,364 - $470,692
29,091 Added 6.43%
481,834 $4.06 Million
Q3 2023

Nov 13, 2023

BUY
$15.96 - $22.18 $652,779 - $907,184
40,901 Added 9.93%
452,743 $7.75 Million
Q2 2023

Aug 11, 2023

SELL
$15.65 - $24.1 $530,707 - $817,255
-33,911 Reduced 7.61%
411,842 $9.56 Million
Q1 2023

May 15, 2023

BUY
$17.48 - $29.09 $696,018 - $1.16 Million
39,818 Added 9.81%
445,753 $7.87 Million
Q4 2022

Feb 13, 2023

BUY
$17.09 - $27.91 $361,333 - $590,101
21,143 Added 5.49%
405,935 $11 Million
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $1.11 Million - $1.5 Million
71,086 Added 22.66%
384,792 $6.65 Million
Q2 2022

Aug 12, 2022

BUY
$13.32 - $19.98 $158,135 - $237,202
11,872 Added 3.93%
313,706 $5.48 Million
Q1 2022

May 13, 2022

SELL
$15.24 - $29.75 $19,796 - $38,645
-1,299 Reduced 0.43%
301,834 $5.13 Million
Q4 2021

Feb 08, 2022

SELL
$25.43 - $34.25 $1.95 Million - $2.62 Million
-76,555 Reduced 20.16%
303,133 $8.21 Million
Q3 2021

Nov 15, 2021

BUY
$28.98 - $39.54 $157,912 - $215,453
5,449 Added 1.46%
379,688 $11.3 Million
Q2 2021

Aug 13, 2021

BUY
$28.5 - $39.37 $2.32 Million - $3.21 Million
81,548 Added 27.86%
374,239 $14.4 Million
Q1 2021

May 12, 2021

SELL
$30.22 - $45.57 $712,194 - $1.07 Million
-23,567 Reduced 7.45%
292,691 $8.93 Million
Q4 2020

Feb 11, 2021

BUY
$23.5 - $52.65 $715,387 - $1.6 Million
30,442 Added 10.65%
316,258 $12.1 Million
Q3 2020

Nov 16, 2020

BUY
$18.85 - $27.0 $801,709 - $1.15 Million
42,531 Added 17.48%
285,816 $6.58 Million
Q2 2020

Aug 14, 2020

BUY
$9.76 - $25.95 $759,757 - $2.02 Million
77,844 Added 47.05%
243,285 $6.05 Million
Q1 2020

May 14, 2020

BUY
$8.9 - $19.08 $146,057 - $313,121
16,411 Added 11.01%
165,441 $1.65 Million
Q4 2019

Feb 14, 2020

BUY
$11.61 - $17.21 $288,113 - $427,083
24,816 Added 19.98%
149,030 $2.14 Million
Q3 2019

Nov 13, 2019

BUY
$10.01 - $16.87 $2,832 - $4,774
283 Added 0.23%
124,214 $1.73 Million
Q2 2019

Aug 13, 2019

BUY
$12.51 - $17.28 $17,976 - $24,831
1,437 Added 1.17%
123,931 $1.82 Million
Q1 2019

May 13, 2019

BUY
$10.26 - $16.24 $423,327 - $670,062
41,260 Added 50.79%
122,494 $1.87 Million
Q4 2018

Feb 12, 2019

BUY
$9.97 - $15.57 $20,079 - $31,357
2,014 Added 2.54%
81,234 $813,000
Q3 2018

Nov 14, 2018

BUY
$14.99 - $22.14 $1.19 Million - $1.75 Million
79,220 New
79,220 $1.28 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.